Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Nu Holdings
NU
5
Liberty Latin America-A
LILA
CN Stock MarketDetailed Quotes
300039 Shanghai Kaibao Pharmaceutical
- 6.07
- 0.000.00%
Not Open Apr 24 15:00 CST
6.35BMarket Cap17.10P/E (TTM)
0.00High0.00Low0lotVolume0.00Open6.07Pre Close0.00Turnover0.00%Turnover Ratio16.91P/E (Static)1.05BShares7.6052wk High1.51P/B5.57BFloat Cap4.9052wk Low7.31Limit Up916.93MShs Float18.28Historical High4.87Limit Down0.00%Amplitude2.60Historical Low0.10Dividend TTM--Avg Price0lotAsk1.65%Div YieldTTM100Lot Size0lotBid
About Shanghai Kaibao Pharmaceutical Company
The company was jointly funded by Shanghai Kaito (Group) Co., Ltd. and Henan Xinyi Pharmaceutical Co., Ltd. The company was listed and traded on the Shenzhen Stock Exchange on January 8, 2010. The company is a comprehensive pharmaceutical enterprise mainly engaged in R&D, production and sales of modern traditional Chinese medicines. The company's main products are: phlegm heat removal injection. Corporate honors: National Comprehensive Assessment of Quality Trustworthy Products - Gureqing; Traditional Chinese Medicine Protected Variety Certificate - Gureqing; 2014 National Quality and Integrity Double Pharmaceutical Enterprise; 2nd China Health Reform Enterprise Support List 2014 Most Socially Influential Enterprise; 2nd China Health Reform Enterprise Support List 2014 Most Socially Influential Enterprise Certificate; 2013 China Model Enterprise of Integrity; 2013 China Model Enterprise of Integrity; 2013 China Model Credit Enterprise Certificate; China Pharmaceutical Daily Executive Director Unit; 2013 Top 20 Most Competitive Pharmaceutical Listed Companies; “2022 Industry Pioneer Award” “National Intellectual Property Advantage” Companies”, “2022 China's Top 100 Traditional Chinese Medicine Enterprises”, “2023 Shanghai Top 100 Emerging Industry Enterprises”, “2023 Shanghai Top 100 Private Manufacturing Enterprises”, “2024 Shanghai Top 50 Growth Enterprises”, “2024 Shanghai Outstanding Academician Workstations”, etc.
Company Profile
Short Name-A上海凯宝
Symbol-A300039
Company NameShanghai Kaibao Pharmaceutical Co.,Ltd.
Listing DateJan 8, 2010
Issue Price38.00
Shares Offered27.40M share(s)
FoundedApr 12, 2000
Legal Representativejingwei mu
General Manageryingbin zhou
Secretaryliwang ren
Accounting FirmLixin Certified Public Accountants Limited
Securities Representativecongying ma
Legal CounselShanghai Tongli Law Firm
Employees373
Phone021-37572069
Office Address88 Chengpu Road, Shanghai Comprehensive Industrial Development Zone
Zip Code201401
Registered Address88 Chengpu Road, Shanghai Comprehensive Industrial Development Zone
Fax021-37572069
Emailkbyydmb@126.com
Websitehttp://www.xykb.com
Business License310226000171574
BusinessPharmaceutical production (small-volume injections, tablets, hard capsules, granules, mixtures, syrups, pills (drops), traditional Chinese medicine extraction workshops), agricultural and sideline products acquisition. (The above scope of business involves operating under license to operate under license)
Company Executives
- Name
- Position
- Salary
- jingwei mu
- Chairman, Directors, Chairman of the Strategy Committee, Audit Committee Member, Nomination Committee Members
- 761.00K
- liwang ren
- Directors, Board Secretary
- 309.50K
- jianzhong liu
- Directors, Deputy General Manager, Strategy Committee Member
- 472.60K
- yingbin zhou
- Directors, General Manager, Strategy Committee Member, Member of the Remuneration and Assessment Committee
- 461.30K
- guoming wang
- Directors
- 312.00K
- shuzhong jing
- Directors
- 323.40K
- zuguang ye
- Independent Directors, Chairman of the Remuneration and Assessment Committee, Strategy Committee Member
- 75.00K
- zhenni li
- Independent Directors, Strategy Committee Member, Nomination Committee Members, Chairman of the Audit Committee
- 75.00K
- hong ma
- Independent Directors, Audit Committee Member, Member of the Remuneration and Assessment Committee, Chairman of the Nomination Committee
- 75.00K
- congying ma
- Securities Affairs Representative
- --
- dongsheng xue
- Chairman of the Supervisory Board, Auditors
- 316.90K
- keji zhao
- Shareholder Supervisors
- 167.10K
- yingjun zhu
- Deputy General Manager
- 240.60K
- youlong chen
- Chief Financial Officer
- 655.80K
- qingli liu
- Employee Supervisors
- --
Market Insights
Warren Buffett Portfolio Warren Buffett Portfolio
Buffett's holdings are the latest portfolio from Berkshire Hathaway. Regarded as a top investor, his trades often signal the market and influence the industry. Buffett's holdings are the latest portfolio from Berkshire Hathaway. Regarded as a top investor, his trades often signal the market and influence the industry.
Unlock Now
Discussing
2025 Buffett shareholders' meeting: What's the new buzz in value investing?
🎙️Discussion 1. In the face of market changes, do you prefer to stick with growth stocks or switch to value stocks? 2. Based on the current
Moomoo News Global
Apr 9 20:29
Learning From Buffett: Investing Wisely Amid Market Volatility Triggered by Trump's Tariffs